Tight Control of Gouty Arthritis Compared to Usual Care
Launched by UNIVERSITY OF EDINBURGH · Aug 18, 2022
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to manage gout, a painful condition caused by the buildup of urate crystals in the joints. The researchers want to see if a self-management approach, where patients can monitor their urate levels at home using a simple finger prick test and a smartphone app called GoutSMART, can reduce the number of gout flares better than standard care. In the past, many patients haven't received effective treatment, and this trial aims to find out if actively adjusting medication based on personal urate levels leads to better control of the condition over two years.
To participate in the trial, you need to be at least 18 years old and have experienced at least one gout flare in the past year. You'll also need a smartphone to use the GoutSMART app. During the trial, you'll be randomly assigned to either use the self-management approach or continue with usual care. It's important to know that some people may not be eligible if they're already on maximum medication for gout or have certain health conditions. Overall, this trial hopes to provide better options for managing gout and improving patients’ quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provision of informed consent.
- • Age ≥18 years.
- • Patient has sustained at least one flare of gout in the previous 12 months.
- • Confirmed clinical diagnosis of gout as per ACR/EULAR criteria
- • Serum urate \>0.36mm/L.
- • Patient has a smart phone and is able to install GoutSMART application.
- Exclusion Criteria:
- • Subject unable to provide consent
- • Patient on maximum urate lowering therapy or where therapy cannot be escalated further due to intolerance/adverse reaction to either allopurinol or febuxostat.
- • End stage renal failure/transplant
- • Current prescription of medication known to interact with xanthine oxidase inhibitors such as azathioprine or mercapto-purine.
About University Of Edinburgh
The University of Edinburgh, a prestigious institution renowned for its commitment to research excellence and innovation, serves as a leading clinical trial sponsor dedicated to advancing healthcare through rigorous scientific inquiry. With a strong emphasis on multidisciplinary collaboration, the university facilitates cutting-edge clinical studies that aim to explore novel therapies and improve patient outcomes. Leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, the University of Edinburgh is at the forefront of translating scientific discoveries into practical applications, thereby contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Philip L Riches, FRCP, PhD
Principal Investigator
NHS Lothian
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials